Skip to Main Content

Paper Details

A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.
CNS Oncol
20
2022
GBM, MGMT, MGMT promoter, WP1066, diarrhea, glioblastoma, human, nausea, p-STAT3, patients, recurrent glioblastoma, recurrent malignant glioma
Author NameAffiliation
John F de GrootUniversity of California San Francisco
Jun WeiThe University of Texas MD Anderson Cancer Center
Rebecca A HarrisonThe University of Texas MD Anderson Cancer Center
Gregory N FullerThe University of Texas MD Anderson Cancer Center
Gregory N FullerThe University of Texas MD Anderson Cancer Center
Jason T HuseThe University of Texas MD Anderson Cancer Center
Raymond SawayaThe University of Texas MD Anderson Cancer Center
Ganesh RaoThe University of Texas MD Anderson Cancer Center
Waldemar PriebeThe University of Texas MD Anderson Cancer Center
Amy B HeimbergerNorthwestern University, Feinberg School of Medicine
Amy B HeimbergerMalnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
  • 1 - 11

Datasets

Release 1.2